Podcast Episodes
Back to Search
Sickle Cell Gene Therapies Reach Patients, Moderna Cuts, Obesity Pill Race and ESMO 2024
After their groundbreaking approval last year, infusions of Vertex and CRISPR Therapeutics’ and bluebird bio’s sickle cell gene therapies have begun,…
1 year, 9 months ago
AI Promises: Funding Data Literacy and Reality First
As 2024 closes, it is only right to discuss where we are when it comes to AI and where we will be in the future.
As technology continues to evolve a…
1 year, 9 months ago
BioMarin Fails to Reassure Investors, Terns Moves Forward in Obesity, ESMO Excitement
Summit Therapeutics made headlines this weekend at the 2024 World Conference on Lung Cancer, revealing that its bispecific antibody outperformed Keyt…
1 year, 9 months ago
Lilly’s DTC Obesity Push, Layoffs, and an Eye on Ocular Diseases
Eli Lilly shook up the weight loss market again last week, announcing plans to sell single-dose vials of its blockbuster GLP-1 drug Zepbound directly…
1 year, 10 months ago
Future-Proofing: Inclusive and Protective Patient Strategies
As the legal landscape continues to evolve, the uncertainty surrounding diversity, equity and inclusion (DEI) initiatives increases though the life s…
1 year, 10 months ago
A Tough Ending, New Beginnings and China-U.S. Biopharma Relations
Gene editing startup Tome Biosciences is laying off nearly its entire workforce, as biopharma companies continue to face challenges in the current ma…
1 year, 10 months ago
New IRA Drug Prices, Lots of Layoffs, Moderna’s Vaccine Opportunity
With the Democratic National Convention underway, the Biden Administration’s announcing the first 10 drug prices negotiated under the under the Infla…
1 year, 10 months ago
Eyes Wide Open: Gaining Patient Trust in the Face of Evolving Women’s Health Policies in State Legislations
In the second part of the discussion, our guests address clinical trial design which if done without careful consideration of the patient population …
1 year, 10 months ago
Lykos Rejection, Pfizer’s RSV Win, Lilly Vs. Novo and More
In one of the year’s most highly anticipated decisions, the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy for post-traumatic stress disorder…
1 year, 10 months ago
Pharma Campaign Contributions, Vaccine Hiccups and Lykos’ Moment of Truth
This week, Kamala Harris selected Minnesota Governor Tim Walz as her running mate. In July, Harris’ campaign netted a whopping $310 million—so where …
1 year, 11 months ago